If the reason UK pays less is because of the negotiating leverage of the NHS, then why was the cash-pay (non-negotiated) UK price so much lower than the U.S. cash price?
All of this will continue until Medicare publishes its negotiated prices on ozempic in November.
What’s frustrating about list prices is that anyone that wants the drug but can’t get their insurance to pay has to pay the list price. I’m a type 1 diabetics. I can’t get my insurance to pay, but glp1s have changed my life for the better. I’m lucky I can afford to pay the compounders and they haven’t been shut down yet, but I’m well off.
If the reason UK pays less is because of the negotiating leverage of the NHS, then why was the cash-pay (non-negotiated) UK price so much lower than the U.S. cash price?
All of this will continue until Medicare publishes its negotiated prices on ozempic in November.
What’s frustrating about list prices is that anyone that wants the drug but can’t get their insurance to pay has to pay the list price. I’m a type 1 diabetics. I can’t get my insurance to pay, but glp1s have changed my life for the better. I’m lucky I can afford to pay the compounders and they haven’t been shut down yet, but I’m well off.